Area of research
Molecular Biology · Surgery
Research interest
Research interests include Cholangiocarcinoma and Gallbladder Cancer Studies, Hepatocellular Carcinoma Treatment and Prognosis, Epigenetics and DNA Methylation, and RNA modifications and cancer.
Tet2 deficiency-induced expansion of monocyte-derived macrophages promotes liver fibrosis.
Spatiotemporal multi-omics analysis uncovers NAD-dependent immunosuppressive niche triggering early gastric cancer
Lysine‐specific demethylase 1 deletion reshapes tumour microenvironment to overcome acquired resistance to anti‐programmed death 1 therapy in liver cancer
Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma
Ficolin 3 promotes ferroptosis in HCC by downregulating IR/SREBP axis-mediated MUFA synthesis
N-linked glycosylation of PD-L1/PD-1: an emerging target for cancer diagnosis and treatment
Proteomic and metabolomic features in patients with HCC responding to lenvatinib and anti-PD1 therapy
The tRNA Gm18 methyltransferase TARBP1 promotes hepatocellular carcinoma progression via metabolic reprogramming of glutamine
N-linked glycosylation of PD-L1/PD-1: an emerging target for cancer diagnosis and treatment.
A <scp>Transformer‐Based</scp> microvascular invasion classifier enhances prognostic stratification in <scp>HCC</scp> following radiofrequency ablation
The tRNA Gm18 methyltransferase TARBP1 promotes hepatocellular carcinoma progression via metabolic reprogramming of glutamine.
PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy
PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti-PD-1 Immunotherapy.
WDR4/TRIM28 is a novel molecular target linked to lenvatinib resistance that helps retain the stem characteristics in hepatocellular carcinomas
Loss of 5-hydroxymethylcytosine induces chemotherapy resistance in hepatocellular carcinoma via the 5-hmC/PCAF/AKT axis
Oncogenic miR-93-5p/Gal-9 axis drives CD8 (+) T-cell inactivation and is a therapeutic target for hepatocellular carcinoma immunotherapy
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma
The Intratumoral Bacterial Metataxonomic Signature of Hepatocellular Carcinoma
Ten‐eleven translocation‐2 inactivation restrains IL‐10‐producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma
The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion
Regulation of cohesin‐mediated chromosome folding by PDS5 in mammals
Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma
Using deep learning to predict microvascular invasion in hepatocellular carcinoma based on dynamic contrast-enhanced MRI combined with clinical parameters
The progress of immune checkpoint therapy in primary liver cancer
STING signaling activation inhibits HBV replication and attenuates the severity of liver injury and HBV-induced fibrosis
CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
An integrative analysis of genome-wide 5-hydroxymethylcytosines in circulating cell-free DNA detects noninvasive diagnostic markers for gliomas
CircRNA UBAP2 serves as a sponge of miR-1294 to increase tumorigenesis in hepatocellular carcinoma through regulating c-Myc expression
Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma